Disc Medicine’s (IRON) Outperform Rating Reiterated at Wedbush

Wedbush reiterated their outperform rating on shares of Disc Medicine (NASDAQ:IRON) in a research note issued to investors on Monday, RTT News reports. They currently have a $75.00 price target on the stock, up from their prior price target of $60.00. Wedbush also issued estimates for Disc Medicine’s Q4 2024 earnings at ($0.89) EPS, FY2024 earnings at ($3.92) EPS, Q1 2025 earnings at ($0.92) EPS, Q2 2025 earnings at ($0.95) EPS, Q3 2025 earnings at ($0.98) EPS, Q4 2025 earnings at ($1.01) EPS, FY2025 earnings at ($3.86) EPS, FY2026 earnings at ($3.96) EPS, FY2027 earnings at ($1.62) EPS and FY2028 earnings at $6.85 EPS.

A number of other research analysts have also commented on the company. Cantor Fitzgerald reissued an “overweight” rating and set a $85.00 price target on shares of Disc Medicine in a report on Tuesday, October 15th. Jefferies Financial Group started coverage on shares of Disc Medicine in a research report on Wednesday, October 23rd. They set a “buy” rating and a $89.00 price target on the stock. HC Wainwright reiterated a “buy” rating and set a $70.00 price objective on shares of Disc Medicine in a research note on Monday, October 28th. Scotiabank started coverage on Disc Medicine in a research report on Wednesday, October 16th. They issued a “sector outperform” rating and a $62.00 target price for the company. Finally, Raymond James raised Disc Medicine from an “outperform” rating to a “strong-buy” rating and boosted their price objective for the stock from $66.00 to $110.00 in a research note on Monday. Nine investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $80.20.

Disc Medicine Price Performance

Shares of IRON opened at $64.80 on Monday. The firm has a fifty day moving average of $49.06 and a 200-day moving average of $43.19. Disc Medicine has a 1 year low of $25.60 and a 1 year high of $77.60.

Disc Medicine (NASDAQ:IRON) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($1.03) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.11) by $0.08. Analysts expect that Disc Medicine will post -4.09 earnings per share for the current year.

Insider Transactions at Disc Medicine

In other Disc Medicine news, Director William Richard White sold 7,136 shares of Disc Medicine stock in a transaction that occurred on Monday, November 4th. The shares were sold at an average price of $58.61, for a total value of $418,240.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold 7,538 shares of company stock valued at $437,875 in the last three months. Corporate insiders own 4.24% of the company’s stock.

Institutional Trading of Disc Medicine

A number of institutional investors and hedge funds have recently modified their holdings of IRON. Amalgamated Bank raised its holdings in Disc Medicine by 76.9% in the 2nd quarter. Amalgamated Bank now owns 568 shares of the company’s stock worth $26,000 after acquiring an additional 247 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Disc Medicine by 45.7% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,075 shares of the company’s stock worth $54,000 after purchasing an additional 337 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of Disc Medicine during the 2nd quarter worth about $129,000. SG Americas Securities LLC boosted its stake in Disc Medicine by 44.2% during the 2nd quarter. SG Americas Securities LLC now owns 4,071 shares of the company’s stock valued at $183,000 after purchasing an additional 1,247 shares during the period. Finally, ProShare Advisors LLC acquired a new stake in Disc Medicine in the 1st quarter valued at approximately $211,000. 83.70% of the stock is currently owned by institutional investors and hedge funds.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.